Merck & Co Inc (MRK) Valuation

Based on the GoodMoat Target of $189.57, the current price of $119.37 implies a margin of safety of approximately 37%. According to the framework's valuation bands, a margin of safety above 40% is considered deeply undervalued, while 20–40% is favourable. Merck's 37% margin of safety falls squarely into the favourable range, indicating the stock is priced well below its estimated intrinsic value. The forward P/E of 16.2 is also attractive when contextualized. It sits below the typical sector average for large-cap pharmaceuticals and is reasonable for a company with a 5% revenue growth and a high 34.7% Return on Equity. A PEG ratio calculation (P/E of 16.2 divided by 5% growth) yields a value of 3.24, which is above the favourable threshold of <1.0, indicating the market is not pricing in significant growth acceleration. However, the low absolute P/E and high profitability metrics (28.1% profit margin, 32.6% operating margin) provide a foundation of value. The 4.2% Free Cash Flow Yield and 2.76% dividend yield further contribute to the total potential shareholder return, supporting the case that the stock is not expensive relative to its underlying financial quality.